High frequency of helicobacter negative gastritis in patients with Crohn’s disease

L Halme, P Kärkkäinen, H Rautelin, T U Kosunen, P Sipponen

Abstract
The frequency of gastric Crohn’s disease has been considered low. This study was undertaken to determine the prevalence of chronic gastritis and Helicobacter pylori infection in patients with Crohn’s disease. Oesophagastroduodenoscopy was performed on 62 consecutive patients suffering from ileocolonic Crohn’s disease. Biopsy specimens from the antrum and corpus were processed for both histological and bacteriological examinations. H pylori antibodies of IgG and IgA classes were measured in serum samples by enzyme immunoassay. Six patients (9.7%) were infected with H pylori, as shown by histology, and in five of them the infection was also verified by serology. Twenty one patients (32%) had chronic H pylori negative gastritis (negative by both histology and serology) and one of them also had atrophy in the antrum and corpus. Granulomas were found in four patients. The characteristic appearance of H pylori negative gastritis was focal and mostly mild inflammation resembling the inflammatory changes seen in the gut in Crohn’s disease. Patients with H pylori negative chronic gastritis had a significantly more active disease in their gut than those with normal gastric mucosa (p<0.01). It is concluded that H pylori positive gastritis is rare, while H pylori negative gastritis is relatively common in patients with Crohn’s disease. H pylori negative ‘Crohn’s gastritis’ seems to be associated with active Crohn’s disease.

(Gut 1996; 38: 379–383)

Keywords: Crohn’s disease, gastritis, Helicobacter pylori.

The frequency of gastroduodenal Crohn’s disease (CD) has been reported as 2–4% in patients with disease affecting the lower gastrointestinal tract.1 Recent reports indicate, however, that the frequency is higher, even more than 30%, especially in children and adolescents.2 Sarcoïd granulomas, diagnostic for CD, are common in children and in patients with a short history of the disease. If granulomas are absent, gastroduodenal CD is diagnosed by combining the clinical, radiological, endoscopic, and histological findings.3 5 More than 90% of patients with duodenal ulcers have gastritis associated with Helicobacter pylori infection.6 7 Recent reports have suggested that CD can be one of the main causes of H pylori negative duodenal ulcers.8 9

In a previous study we described upper gastrointestinal lesions characteristic of CD in 17% of patients with ileocolonic manifestations of the disease.10 Furthermore, 40% of these patients had chronic, non-specific gastritis. This study aimed to determine the prevalence of chronic gastritis and that of H pylori infection in patients with CD who had undergone oesophagastroduodenoscopy (OGDS) at the Fourth Department of Surgery, Helsinki University Hospital between 1989 and 1994.

Patients and methods
During a five year period from September 1989 to August 1994, OGDS was performed on 62 consecutive patients with CD to establish the distribution of their disease. During the study period, the OGDS was repeated (one to seven times) – on three patients because of anaemia and on five patients because of upper gastrointestinal complaints. Before OGDS, all patients were interviewed and their medical records were examined in order to register upper gastrointestinal symptoms or diseases or any other underlying diseases as well as possible antimicrobial and other medical treatments.

In all 62 patients (age: mean 41 years; range 23–76 years, gender: 35 males) the diagnosis of CD was based on the criteria described by Lennard-Jones.11 The mean (SD) duration of CD was 8.4 (5.4) years, range 0.5–23.4 years. A small bowel disease pattern had been diagnosed in 33% of the patients, a large bowel one in 22%, and a combined small and large bowel pattern in 45% of the patients. Before the primary OGDS, 76% of the patients had undergone at least one bowel resection. In two patients, duodenal involvement (based on radiological and endoscopic findings of duodenal strictures) had been previously diagnosed. One further patient had undergone gastric resection for stenosis of the pylorus, and granulomatous gastritis of an unknown origin had been verified three years before the diagnosis of CD in the ileum. In one patient, hypertrophic gastritis had been confirmed earlier on the basis of gastric specimens taken at laparotomy. In 14 of the 62 patients the primary OGDS was performed during an exacerbation of CD (duration of symptoms less than two weeks) in the gut, whereas 31 of the 62 patients had chronically active disease (duration of symptoms more than a month) in the gut and the disease of 17 patients was totally inactive when the OGDS was done. CD was classified as active if there was endoscopically and histologically or radiologically proved acute inflammation in the gut and the modified Harvey-Bradshaw index was >3.12
TABLE 1  Prevalence of Helicobacter pylori infection as determined by histological findings of the gastric biopsy specimens (n = 62) and by detection of H pylori antibodies in serum samples (n = 61)

<table>
<thead>
<tr>
<th>Type of gastritis</th>
<th>No (%)</th>
<th>Histology H pylori +ve</th>
<th>Antibodies H pylori +ve</th>
</tr>
</thead>
<tbody>
<tr>
<td>Granulomatous gastritis</td>
<td>1 (2)</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Hyperplastic gastritis</td>
<td>1 (2)</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Chronic superficial gastritis</td>
<td>22 (35)</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Atrophic gastritis</td>
<td>3 (5)</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Acute erosions</td>
<td>4 (6)</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Normal gastric mucosa</td>
<td>31 (50)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>62</strong></td>
<td><strong>6</strong></td>
<td><strong>5</strong></td>
</tr>
</tbody>
</table>

**ENDOSCOPY**

Multiple (three or more) biopsy samples from the antrum, corpus, and duodenum were systematically taken from macroscopically pathological and normal looking mucosal areas. Biopsy specimens from the oesophagus were taken only from macroscopically abnormal areas.

**HISTOLOGY**

The biopsy specimens were fixed in formalin and embedded in paraffin. The tissue sections were performed for morphological and bacteriological examination, using haematotoxyn-eosin (HE), Alcian blue (pH 2-5) – periodic acid schiff, and modified Giemsa stains. All specimens were examined for typical features of Crohn’s disease by two pathologists (PK and PS). The presence and type of chronic gastritis in the specimens taken from the antrum and corpus of the stomach were interpreted and scored according to the Sydney system.13 The presence of *H pylori* infection in the specimens taken from the antrum and corpus was graded as 0 (no bacteria), 1 (minimal colonisation), 2 (moderate colonisation), and 3 (extensive colonisation).

**ANTIBODY ASSAY**

Serum samples, taken at the time of OGDS, were available from 51 of 62 patients. In 10 further patients serum samples had been collected after the OGDS. One patient died during the study period, and no serum sample was available from him. Antibodies to *H pylori* were measured separately for IgG, and IgA by enzyme immunoassay.14,15 The absorbance readings were converted to reciprocals of the end point titres. The end point titres were the dilutions of the serum at the cut off level defined by the optical densities of the positive reference serum pools at constant dilutions. The lower limits of raised titres (expressed as reciprocals) were 700 for IgG and 100 for IgA.

**STATISTICAL METHODS**

The Pearson’s *x^2* test and the Fisher’s exact test were used.

**Results**

**ENDOSCOPICAL FINDINGS**

Twenty two patients had redness or oedema in the antrum or corpus mucosa. One patient had senosis of the pylorus, three further patients had stenosis of the duodenum, and one patient showed an incipient stenosis in the cardia. One patient had a deep ulceration in the cardia below the gastro-oesophageal junction, and five further patients had aphthous or deep longitudinal ulcerations in the duodenum.

**HISTOLOGICAL FINDINGS IN THE GASTRIC MUCOSA**

Six (9.7%) of the 62 patients studied showed *H pylori* in their gastric biopsy specimens stained by modified Giemsa (Table I). The density of colonisation in the antral mucosa was moderate in two and extensive in four cases. *H pylori* infection was graded as minimal in three patients, moderate in two, and extensive in one of the patients, when the mucosa of the body was considered. The histological findings of the biopsy specimens of the 62 patients are shown in Table I.

Twenty one patients (34%) had *H pylori* negative chronic gastritis. A characteristic appearance was a focal, patchy inflammation with polymorphonuclear, eosinophilic, and mononuclear cells destroying parts of the crypts (Fig 1). In a third of these patients the inflammation was graded as moderate or severe, and in these seven patients especially, the inflammatory changes in the gastric mucosa resembled those seen in the acute involvement of the gut in Crohn’s disease. The patients with *H pylori* negative gastritis had a significantly more active disease in the gut than those with normal gastric mucosa (p<0.01, Table II).

Four of the 62 patients showed microgranulomas in the gastric mucosa. One patient with *H pylori* positive atrophic gastritis and a deep ulceration and an incipient stenosis in the upper cardia had a microgranuloma at the edge.
of the ulceration. On patient who had undergone gastric resection three years before CD was diagnosed showed granulomatous H pylori positive gastritis verified in the resection specimen (Fig 2). Furthermore, two patients with H pylori negative gastritis in the antrum showed microgranulomas.

H PYLORI ANTIBODIES

Five patients (8.1%) had high H pylori antibody titres in the IgG class (Tables I and III) and three of these patients also had raised IgA antibody titres. One patient with acute erosions and extensive colonisation of H pylori in the biopsy specimens did not show high antibody titres against H pylori.

PREVIOUS ANTIMICROBIAL TREATMENTS AND OTHER MEDICATIONS

None of the patients studied had been treated for H pylori infection. Two patients with H pylori negative gastritis had been given ranitidine because of gastrointestinal symptoms, and one further patient with H pylori positive gastritis had received omeprazole earlier. A total of 46 patients (77%) had undergone gastrointestinal surgery and had been given antimicrobial prophylaxis or antimicrobial therapy lasting from one to 10 days and consisting of metronidazole and cephalosporin or metronidazole and amoxicillin. There was no association between gastrointestinal surgery and the presence or absence of H pylori infection (Table III).

Medical treatments for Crohn’s disease before the endoscopy are shown in Table III. Thirty eight patients had not received any medical treatment in the three months immediately before the endoscopy, but some had had antimicrobial prophylaxis or antimicrobial therapy of short duration earlier in connection with bowel surgery (Table III). There were no significant differences, however, in any medical treatment in the patients with gastritis or normal mucosa or in those with or without H pylori infection (Table III).

No use of non-steroidal anti-inflammatory drugs or heavy alcohol consumption were reported. Fourteen of the patients were smokers but only three of these had H pylori negative gastritis.

**Discussion**

The frequency of gastric CD has previously been considered to be low. However, this might have been due to difficulties in diagnosing typical radiological or endoscopic findings, such as strictures, aphthous or longitudinal ulcerations or cobble stone, as well as granulomas in histological specimens which are required for the diagnosis. Furthermore, it has been difficult to differentiate the inflammatory lesions seen in CD from other gastroduodenal diseases, particularly the peptic ulcer disease and ordinary H pylori positive gastritis. In the present study, gastric microgranulomas were detected only in four (6.5%) of the 62 patients. However, a third of the patients showed chronic H pylori negative gastritis, the inflammatory changes of which resembled those seen in the active CD in the gut. Thus, it seems that gastric involvement of CD is not as rare as previously thought.

Most duodenal ulcer patients have antral gastritis, and in 90–100% of them H pylori is found in the antral mucosa. According to a previous study of a Finnish population, the prevalence of H pylori negative, non-atrophic gastritis was about 6% in 1977, 1985, and 1992. In the present study, only six patients with gastritis were shown to be infected by H pylori, as determined by the histological
examination of Giemsa stained gastric biopsy specimens. The colonisation of \( H\) \( pylori\) can be patchy on the gastric mucosa and therefore the prevalence of \( H\) \( pylori\) in the present patients was confirmed by the determination of \( H\) \( pylori\) antibodies in the serum samples. All except one of the patients with histologically proved \( H\) \( pylori\) infection showed raised antibodies against \( H\) \( pylori\). No further \( H\) \( pylori\) positive patients were found by serology. Thus, the prevalence of \( H\) \( pylori\) infection in CD seems to be low.

In a recent report by El-Omar et al the prevalence of \( H\) \( pylori\) infection was low in patients with an inflammatory bowel disease, including both the patients with ulcerative colitis and those with CD. It was suggested that this might have been due to the eradication of \( H\) \( pylori\) infection in patients with long term treatment with sulphasalazine. In the present study, 10 patients had been treated with long term sulphasalazine (Table III), and two of these patients were still \( H\) \( pylori\) positive. In addition, as other antimicrobial treatments of long or short duration were considered, no significant differences were found between patients with gastritis or normal mucosa and between patients with or without \( H\) \( pylori\) infection (Table III). Although the medical treatments given to these patients would, by some mechanism, have led to the eradication of \( H\) \( pylori\), the histological findings of focal inflammation can hardly be explained as sequelae of the eradication of \( H\) \( pylori\).

Our results support an earlier assumption that CD is a generalised inflammatory disease of the whole gastrointestinal tract. Before the era of \( H\) \( pylori\), focal gastric inflammatory changes similar to the present findings were described on the gastric mucosa of patients with CD by Korelitz et al and Schmitt-Moormann et al. However, in those reports the diagnosis of gastric CD was confirmed by concomitant findings of granulomas and other findings characteristic of CD. As the patients with \( H\) \( pylori\) negative gastritis had active disease in the gut significantly more often than those with normal gastric mucosa, we suggest that gastric manifestations could be used as markers of an exacerbation of CD in the gut.

| Table III: Helicobacter pylori antibody titres and medical treatment of patients with Crohn’s disease (CD). There were no significant differences in medical therapy between patients with gastritis or with normal mucosa and between patients with or without \( H\) \( pylori\) infection. |

<table>
<thead>
<tr>
<th>( H) ( pylori) –ve patients</th>
<th>( H) ( pylori) +ve patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chronic gastritis ((n=22))</td>
<td>Erosions ((n=3))</td>
</tr>
<tr>
<td>Sulphasalazine</td>
<td>3</td>
</tr>
<tr>
<td>5-aminosalicylic acid</td>
<td>4</td>
</tr>
<tr>
<td>Metronidazole or ciprofloxacin</td>
<td>4</td>
</tr>
<tr>
<td>Immunosuppressive drugs</td>
<td>–</td>
</tr>
<tr>
<td>Corticosteroids (within 3 mths)</td>
<td>3</td>
</tr>
<tr>
<td>History of antimicrobial prophylaxis or therapy in connection with previous bowel surgery*:</td>
<td></td>
</tr>
<tr>
<td>1–3 d</td>
<td>7</td>
</tr>
<tr>
<td>4–10 d</td>
<td>8</td>
</tr>
<tr>
<td>No antimicrobial therapy or previous surgery</td>
<td>5</td>
</tr>
<tr>
<td>( H) ( pylori) antibody titre t:</td>
<td></td>
</tr>
<tr>
<td>Median (range) IgG titre</td>
<td>50 (50–200)</td>
</tr>
<tr>
<td>Median (range) IgA titre</td>
<td>5 (5–20)</td>
</tr>
</tbody>
</table>

*In all patients bowel surgery was performed at least a year prior to endoscopy. Antimicrobial prophylaxis consisted of metronidazole and cephaloridine or metronidazole and aminoglycoside. The lower limit of raised titres was 700 for IgG and 100 for IgA. One patient with \( H\) \( pylori\) in the biopsy specimen did not show raised \( H\) \( pylori\) antibody titres.

Frequency of helicobacter - ve gastritis in CD


High frequency of helicobacter negative gastritis in patients with Crohn's disease.

L Halme, P Kärkkäinen, H Rautelin, T U Kosunen and P Sipponen

Gut 1996 38: 379-383
doi: 10.1136/gut.38.3.379

Updated information and services can be found at:
http://gut.bmj.com/content/38/3/379

Email alerting service
These include:
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Crohn's disease (932)
- Stomach and duodenum (1689)
- Campylobacter, Salmonella, Shigella, Escherichia coli (242)
- Helicobacter pylori (218)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/